Calidi Biotherapeutics Posts Q3 2026 Results, Cuts Costs
Calidi Biotherapeutics reported Q3 2026 financial results highlighting $1.2M gross proceeds from a direct offering and a reduction in administrative expenses. The company presented new preclinical data supporting its RedTail platform and executed a restructuring plan.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed